Physician profile
Jill Mclaughlin
NPI 1386096337
$2,654.26
in general payments reported to CMS, 2019-2025
27 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $923 · 2023: $418 · 2024: $312 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $311.97 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $305.93 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $283.45 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $269.34 | 2021-2022 | |
| Esperion Therapeutics, INC. | $208.96 | 2021-2022 | |
| Atricure, INC. | $169.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.90 | 2021-2025 | Jardiance |
| Abiomed | $150.43 | 2022-2025 | |
| Kite Pharma, INC. | $93.45 | 2023 | |
| Janssen Pharmaceuticals, INC | $89.47 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $86.31 | 2024-2025 | Wegovy, Ozempic |
| Chiesi USA, INC. | $82.33 | 2021-2025 | Juxtapid, Kengreal |
| Abbott Laboratories | $61.52 | 2021-2022 | |
| Boston Scientific Corporation | $46.98 | 2021-2024 | Watchman Flx, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $46.72 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.07 | 2022 | |
| Amarin Pharma, INC. | $36.89 | 2021 | |
| Daiichi Sankyo INC. | $28.23 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $26.91 | 2024 | Onpattro |
| Kestra Medical Technology Services, INC. | $22.73 | 2022 | |
| Medtronic, INC. | $22.54 | 2022 | |
| Philips North America LLC | $19.55 | 2025 | Mcot |
| Sanofi-Aventis U.S. LLC | $19.33 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $19.15 | 2024 | Evkeeza |
| Pfizer INC. | $16.56 | 2021 | |
| Scpharmaceuticals INC. | $16.00 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $14.41 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.